Broad Institute and UPenn-linked cardiovascular disease drug developer Verve priced an upscaled initial public offering above its range.

The oncology therapy developer has filed for an IPO just two years after emerging from stealth to advance Harvard and Stanford research.

Centessa, formed earlier this year through a ten-way merger involving multiple spinouts, has completed a listing in the US.

UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.

The Lund research-based oat milk brand has floated in a $1.43bn IPO on the Nasdaq Global Select Market after pricing shares at $17.

SUNY Polytechnic University-backed Norsk Titanium has begun trading on Euronext Growth Oslo.

Yale's immunological disease treatment developer floated its shares below its initial price range in an IPO in the US.

York spinout Cizzle Biotechnology has undertaken a reverse merger with Bould Opportunities to list on the London Stock Exchange.

MIT spinout Ginkgo Bioworks will go public through a reverse merger with Soaring Eagle Acquisition Corp to list on the Nasdaq Capital Market.

Cambridge’s gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.